Our data indicate that PDLIM2 plays a dual role: (i) as an EMT-supporting and hypoxia-responding 4 5 oncoprotein in luminal breast cancer cells, and (ii) as an epithelial phenotype-maintaining tumor 4 6 suppressor in normal epithelial breast cells. 4 7 KEYWORDS 4 8 PDLIM2; EMT; metastasis; luminal A breast cancer; hypoxia; MCF10A cells 4 9 5 0
Department of Biochemistry 1 5
Kamenice 5 1 6
62500 Brno 1 7
Czech Republic 1 8
Phone: +420-549493251 1 9 E-mail: bouchal@chemi.muni.cz 2 0 2 1 ABSTRACT 2 2 Background 2 3 PDZ and LIM domain protein 2 (PDLIM2) is a cytoskeletal and nuclear effector that regulates the 2 4 activity of several transcription factors (e.g., NF-κB, STAT), and its deregulation has been associated 2 5
with oncogenesis. Our recent study identified PDLIM2 as a protein associated with the lymph node 2 6 metastasis of low grade luminal A breast cancer tissues. Here, we aim to understand this association at 2 7 the molecular and cellular levels. To investigate the link between PDLIM2 and epithelial-to-mesenchymal transition (EMT), stably 3 0 transduced MCF7-PDLIM2 cells, and MCF7 or MCF10A cells with PDLIM2 protein levels modified 3 1 using siRNA or PDLIM2 gene carrying plasmid, were used. Additionally, MCF7 and MCF10A cells 3 2 were exposed to hypoxic conditions and TGFβ1 treatment. EMT was monitored using immunoblotting 3 3 of EMT markers and atomic force microscopy (AFM). The role of PDLIM2 in cell migration and/or 3 4 invasion was investigated using Transwell assay and xCELLigence system. 3 5
Results

6
First, we observe a positive effect of PDLIM2 overexpression on EMT in MCF7 cells, a model of 3 7 luminal A tumors, using EMT markers and AFM. On the other hand, PDLIM2 helps to maintain the 3 8 epithelial phenotype in MCF10A cells, a model of normal breast epithelial cells. Second, we find that 3 9 exposure of the MCF7 cells to hypoxic conditions increases levels of PDLIM2 and carbonic 4 0 anhydrase-9 (CA-9), a marker of the response to hypoxia. However, none of these effects are observed 4 1 in the MCF10A cells. Third, PDLIM2 overexpression promotes migration, invasion, and proliferation 4 2 and decreases adhesion of the MCF7 cells, but an opposite effect is observed in the MCF10A cells. 4 3 1 3 8 was purified using the standard protocol of the QIAquick PCR Purification Kit (Qiagen). 1 3 9
Construction of the pcDNA3-PDLIM2-GW-DEST plasmid 1 4 0
Gateway technology (Thermo Fisher Scientific) was used to construct the PDLIM2-carrying plasmid. 1 4 1
The cDNA fragment of PDLIM2 was amplified using PCR with Herculase II DNA polymerase, a pair 1 4 2 of specific primers, PDLIM2 TEV forward (5'-1 4 3 GGCTCTGAGAACCTGTACTTCCAGAGCATGGCGTTGACGGTGGATGTG-3', bearing a region 1 4 4 coding the sequence recognized by TEV protease) and PDLIM2 GWs reverse (5'-1 4 5 GTACAAGAAAGCTGGGTTTCAGGCCCGAGAGCTGAGG-3', bearing a stop codon), and a pair 1 4 6 of universal primers, TEV forward (TEV F: 5'-1 4 7 GGGGCTGCTTTTTTGTACAAACTTGTCCGAGACTCTTGG-3') and ATTB2 reverse (ATTB2 R: 1 4 8 5'-GGGGCAGCTTTCTTGTACAAAGTGGGACATGTTCTTTCG-3'). The reaction mixture 1 4 9
contained 1 M betain, 20 μ l of cDNA, 1x reaction buffer, 1 mM dNTP, 1 μ l of Herculase II, specific 1 5 0 primers at 0.1 μ M and universal primers at 0.3 μ M, and nuclease-free water was added to the final 1 5 1 volume of 50 μ l. The PCR program included predenaturation at 95 °C for 1 min and 30 amplification 1 5 2
The lentiviral vector pLENTI-PDLIM2 was prepared in-house according to Gateway® Technology 1 7 0 with the Clonase® II user guide (Invitrogen, 25-0749 MAN0000470). The production of lentiviruses 1 7 1 was performed according to the ViraPower™ Lentiviral Expression Systems user manual (Invitrogen, 1 7 2 25-0501 MAN0000273). Transduction of MCF-7 cells and selection of stably transfected clones were 1 7 3 performed according to the ViraPower™ Lentiviral Expression Systems user manual (Invitrogen, 25-1 7 4 0501 MAN0000273). 1 7 5
Cell transfection 1 7 6
For PDLIM2 suppression, cells were transfected using the Amaxa cell line nucleofector kit 1 7 7 V (LonzaBio). A total of 1.0×10 6 cells cultivated to 70% confluence were harvested and resuspended 1 7 8 in 100 μ l of AMAXA buffer (4 mM KCl, 10 mM MgCl 2 , 120 mM NaH 2 PO 4 /Na 2 HPO 4 , 10 mM 1 7 9 HEPES pH 7.2) together with either anti-PDLIM2 siRNA or control siRNA at a concentration of 600 1 8 0 nM. T024 and P020 transfection programs were used for the transfection of MCF 10A and MCF7 1 8 1 cells, respectively. Plasmid transfection using the polyethylene imine (PEI) method based on 1 8 2 lipofection was used. Cells were cultivated on 6-cm Petri dishes to 60-70% confluence, and 5 μ g of 1 8 3 specific or control plasmid was resuspended together with 15 μ l of PEI (working solution 1 μ g/μl in 1 8 4 water, pH 7) in 0.5 ml of serum-free medium, incubated for 15 minutes at room temperature, poured 1 8 5 onto a dish and further cultivated for 24, 48 or 72 hours. 1 8 6
SDS PAGE and immunoblotting 1 8 7
Cell lysates for SDS PAGE were prepared using hot (95 °C) sample buffer (10% glycerol, 2% 1 8 8 bromophenol blue, 62.5 mM Tris HCl pH 6.8, 2% SDS pH 6.8, 5% mercaptoethanol). SDS PAGE 1 8 9 with a 5% stacking gel and 10% running gel was used for separation as described previously [14] . 1 9 0
Protein lysates in the amount of 20 µg, determined by an RC-DC Protein Assay (Bio-Rad), were run in 1 9 1 the gels and wet-transferred onto PVDF membranes. Membranes were then blocked for 1 hour in 1 9 2 PBS+0.1% Tween 20 (2.68 mM KCl, 0.137 M NaCl, 6.45 mM Na 2 HPO 4 .12H 2 O, 1.47 mM KH 2 PO 4 , 1 9 3 0.89 mM Tween 20) containing 5% nonfat milk and incubated with primary antibody (at the 1 9 4 appropriate dilution, see above) at 4 °C overnight. After incubation, membranes were washed two 1 9 5 times in PBS and once in PBS+0.1% Tween 20 and subsequently incubated with the corresponding 1 9 6 secondary antibody (1:1000) at room temperature for 1 hour and washed again. After 5 min of 1 9 7 incubation of membranes with ECL solution (10 mM luminol, 0.5 mM EDTA, 405 μ M coumaric acid, 1 9 8 200 mM Tris pH 9.4, 8 mM sodium perborate tetrahydrate, 50 mM sodium acetate), immunoreactive 1 9 9 proteins were visualized by enhanced chemiluminescence (ECL) solution using a CCD camera (Alpha 2 0 0 Innotech FluorChem TM SP, Quansys Biosciences, USA). Further details are provided in the Additional file 15: Methods S1. 2 1 1 TGFβ1 treatment and hypoxia 2 1 2 EMT in cells was induced by TGFβ1 treatment or hypoxic conditions. For PDLIM2 protein level 2 1 3 induction and monitoring, TGFβ1 was added to the complete culture medium to a final concentration 2 1 4 of 1 ng/ml, and the cells were cultivated for 24 hours. For cell morphology changes and monitoring, 2 1 5 TGFβ1 at 10 ng/ml was added to serum-free medium after 16 hours of serum starvation, and the cells 2 1 6
were cultivated for 48 hours [21] . Control cells were cultivated in medium without TGFβ1. For 2 1 7 induction of EMT by hypoxia, cells were cultivated in a hypoxic culture hood (Biospherix Xvivo X3, 2 1 8
Biospherix) under a 2% concentration of O 2 for 48, 72 or 96 hours. 2 1 9
Migration and invasion assay 2 2 0
Real-time measurements of cell migration and invasion were performed using the CIM-Plate 16 2 2 1 module of an xCELLigence System RTCA DP real-time cell analyzer (Roche, UK). For invasion 2 2 2 measurement, the top side of the polycarbonate membrane in the upper chamber wells was coated with 2 2 3 Culturex®Basement membrane extract (Trevigen, USA) diluted 1:50 with Coating buffer (Trevigen, 2 2 4 USA) 4 hours prior to the experiment. The CIM plates were then prepared by the addition of 170 µL 2 2 5 of corresponding medium (with 10% FBS as the chemoattractant) into twelve wells of the lower 2 2 6 chamber; four wells filled with 170 µL of serum-free medium served as controls to determine the 2 2 7 background signal. Each well of the upper chamber was filled with 30 µL of serum-free medium. The 2 2 8 plates were inserted into the xCELLigence station in the culture hood (21% O 2 , 5% CO 2 , 37 °C), and 2 2 9 the baseline impedance was measured after 1 hour of equilibration at 37 °C. Cells (5×10 4 cells per well 2 3 0 1 for migration and 1×10 5 cells per well for invasion) were then added to the wells of the upper chamber 2 3 1 in 100 µL of serum-free medium, and the plate was equilibrated again for 30 min at room temperature 2 3 2 and inserted into the xCELLigence once again before the start of measurements. The detailed 2 3 3 arrangement of the plates is shown in Additional file 1: Figure S1 . The xCELLigence analyzer was set 2 3 4
to measure the impedance every 15 min for 24 hours. Normalized cell indexes (CI) were then 2 3 5 calculated as a variable corresponding to the number of migrating or invading cells and statistically 2 3 6 evaluated (part "Statistical analysis"). 2 3 7
Migration and invasion of cells were also measured using a 96-well Transwell assay (Trevigene, 2 3 8 USA). The Transwell assay consists of upper and lower chambers (each with 96 wells) separated by a 2 3 9 porous polyethylene terephthalate (PET) membrane (pore size 8 μ m) localized on the bottom of the 2 4 0 upper chamber wells. For migration measurement, 100 μ l of medium containing 10% FBS (used as a 2 4 1 chemoattractant) was applied to the lower chamber wells, and wells were filled with 100 μ l of serum-2 4 2 free medium were used as controls. Cells (5×10 4 cells per well for migration and 1×10 5 cells per well 2 4 3 for invasion; see Additional file 1: Figure S1 for plate design) were resuspended in serum-free 2 4 4 medium and added to the upper chamber wells. After incubation in a culture hood (21% O 2 , 5% CO 2 , 2 4 5 37 °C) for 24 hours, upper and lower chamber wells were rinsed, cells in the upper chamber wells 2 4 6
were washed away and the migrated or invasive cells on the lower membrane surface were stained 2 4 7 using Calcein AM according to the manufacturer's protocol. After 1 hour of incubation in the culture 2 4 8 hood in the dark, the fluorescence of converted calcein was measured using a Tecan Infinite M100 Pro 2 4 9 (Life Sciences) with an excitation wavelength of 495 nm and emission wavelength of 515 nm. The 2 5 0 number of cells migrating or invading across the membrane was quantified according to fluorescence 2 5 1 values and statistically evaluated (part "Statistical analysis"). The invasion assay was performed 2 5 2 equivalently to the migration measurement assay but with coating of the top side of the polycarbonate 2 5 3 filter in the upper chamber wells with Culturex® Basement membrane extract. 2 5 4
Each experiment was performed with two biological replicates (cells grown on independent plates) per 2 5 5 condition with three technical replicates (wells) for each biological replicate. Two independent 2 5 6 experiments were performed per comparison. To investigate how PDLIM2 is affected by EMT, we induced EMT by TGFβ1 (1 ng/ml for 24 hours) 3 0 3 or by long-term exposure to hypoxia (2% O 2 for 96 hours) and monitored how PDLIM2 responds. 3 0 4
Both treatments led to elevated PDLIM2 protein levels, and successful induction of EMT was 3 0 5 confirmed by decreased levels of the epithelial markers E-cadherin, β -catenin and KRT18 ( Fig. 2A  3  0  6 and Additional file 4: Figure S4 ). Notably, we observed that shorter exposure times to hypoxic 3 0 7 conditions (48 and 72 hours) were still not able to decrease levels of epithelial markers and induce 3 0 8
EMT (see Additional file 5: Figure S5 ); however, PDLIM2 levels increased ( Fig. 2B and Additional 3 0 9
file 5: Figure S5 ), indicating that not only EMT but also hypoxia itself upregulates PDLIM2 levels. 3 1 0
Moreover, levels of carbonic anhydrase-9 (CA9), a marker of the response to hypoxic conditions, were 3 1 1 elevated in MCF7 cells with overexpressed PDLIM2 (Fig. 2C and Additional file 6: Figure S6 ). 3 1 2
In addition to TGFβ1 and hypoxia-induced EMT, we were interested in whether PDLIM2 functionally 3 1 3
interacts with other key cancer players, including p53 and p65. We found that PDLIM2 3 1 4 overexpression decreased both the p53 total protein level as well as its serine 20 phosphorylated, 3 1 5 active form (p-p53 (S20)) ( Fig. 2D and Additional file 7: Figure S7 ). On the other hand, the level of 3 1 6 p65 protein, a key member of the canonical NF-κB pathway, was not affected by any of these 3 1 7 treatments, nor by overexpression or suppression of PDLIM2 (see Fig. 2D and Additional file 7: 3 1 8 Figure S7 ). 3 1 9
PDLIM2 overexpression increases both migration and invasion of MCF7 breast cancer cells 3 2 0
To further verify the pro-tumorigenic role of PDLIM2 on cellular levels, we examined its effect on the 3 2 1 migration and invasion of the MCF7 cells. PDLIM2 overexpression increased the migration 3 2 2 capabilities of these cells as observed by real-time measurement using the xCELLigence system 3 2 3 (p=2.8x10 -4 ) and independently confirmed using a Transwell assay with end-point detection 3 2 4 (p=3.6x10 -5 ) (Fig. 3A) . Overexpression of PDLIM2 also had a similar effect on the invasion of MCF7 3 2 5 cells measured using xCELLigence (p=3.9x10 -4 ) and the Transwell assay (p=1x10 -5 ) (Fig. 3B ). Our 3 2 6 results suggest that PDLIM2 is relevant for regulation of the migration and invasiveness of MCF7 3 2 7 cells. 3 2 8
PDLIM2 overexpression diminishes cell adhesion and increases proliferation of MCF7 cells, 3 2 9
while suppression of PDLIM2 has the opposite effect 3 3 0
Next, we investigated the consequences of PDLIM2 modulation on the adhesion and proliferation of 3 3 1 MCF7 cells. Suppression of PDLIM2 by siRNA significantly augmented the adhesion of MCF7 cells 3 3 2 (*p=1x10 -5 ) compared to control cells; on the other hand, specific overexpression of PDLIM2 3 3 3
considerably decreased adhesion (p=1x10 -5 ) (Fig. 3C ). PDLIM2 suppression also substantially 3 3 4 diminished the proliferation of MCF7 cells (p=1x10 -5 ), in contrast to the dramatic increase in the 3 3 5 proliferation of the MCF7 cells with overexpressed PDLIM2 (p=1x10 -5 ) (Fig. 3D ). These results To ascertain whether the effects related to PDLIM2 levels described in sections above are of general 3 4 1 validity or are context-dependent, we selected another model, MCF10A immortalized human 3 4 2 epithelial breast cells. We either overexpressed or suppressed PDLIM2 in these cells and monitored 3 4 3 the effects of these changes on molecular and cellular levels. The effects of overexpression and 3 4 4 suppression of PDLIM2 on EMT markers are shown in Fig. 4A and Additional file 8: Figure S8 cadherin as well as FAK were increased, indicating EMT. These results suggest that PDLIM2 is 3 5 0 important for maintaining the epithelial phenotype of MCF10A cells. 3 5 1 EMT induction by TGFβ1 decreases PDLIM2 levels, but hypoxia has no effect on PDLIM2 3 5 2 levels in MCF10A cells 3 5 3
To investigate how EMT affects PDLIM2 in MCF10A cells, we induced EMT by treatment with 3 5 4
TGFβ1 (1 ng/ml for 24 hours) and monitored PDLIM2 protein levels. As shown in Fig. 4B and 3 5 5
Additional file 9: Figure S9 , PDLIM2 protein levels were downregulated after EMT induction in 3 5 6
MCF10A cells, in a distinct manner compared to that of MCF7 cells. Successful EMT induction was 3 5 7 confirmed by decreased levels of E-cadherin and increased levels of vimentin and N-cadherin. We also 3 5 8 attempted to induce EMT by exposing the MCF10A cells to hypoxic conditions; however, we did not 3 5 9
observe any changes in E-cadherin and vimentin levels as well as in PDLIM2 protein levels (see 3 6 0 Additional file 10: Figure S10A and S10B). Additionally, we did not observe any change in CA9 3 6 1 levels after PDLIM2 modulation (see Additional file 10: Figure S10C ). These results confirm the 3 6 2 importance of PDLIM2 in the maintenance of the epithelial phenotype and indicate that PDLIM2 does 3 6 3 not play a significant role in the response to hypoxic conditions in MCF10A cells. 3 6 4
PDLIM2 overexpression decreases p53 (S20) phosphorylation in MCF10A cells 3 6 5
To investigate mechanisms of the potential tumor suppressive role of PDLIM2 in MCF10A cells, we 3 6 6 analyzed its effect on p53 levels, p53 phosphorylation (S20) and p65 protein levels. In contrast to 3 6 7 MCF7 cells, overexpression of PDLIM2 had no effect on p53 levels (see Fig. 4A and Additional file 3 6 8 8: Figure S8) ; nevertheless, the active form of this protein, p-p53 (S20), was augmented ( Fig. 4A and 3 6 9
Additional file 8: Figure S8 ). The level of p65 was not affected by overexpression or suppression of 3 7 0 PDLIM2 (see Fig. 4A and Additional file 8: Figure S8) . These results suggest a tumor suppressive role 3 7 1 of PDLIM2 in MCF10A cells. To validate the distinct role of PDLIM2 in MCF10A cells at the cellular level, we examined its effect 3 7 5 on the migration and adhesion of MCF10A cells. PDLIM2 suppression by siRNA was accompanied 3 7 6 by significant augmentation of the migration abilities of the MCF10A cells relative to cells with 3 7 7 endogenous protein levels, as revealed by Transwell assay (p<1x10 -5 ) (Fig. 5A , conditions A, C and 3 7 8 E). Conversely, overexpression of PDLIM2 significantly decreased the migration abilities of the 3 7 9
MCF10A cells (p<1x10 -5 ) relative to cells with endogenous protein levels (Fig. 5A, conditions B , D 3 8 0 and E). As shown in Fig. 5B, PDLIM2 suppression significantly decreased the adhesion of MCF10A Finally, comparison of PDLIM2 protein levels in other breast cancer cell lines (Additional file 11: 3 8 7 Figure S11 ) showed that PDLIM2 levels were low in low invasive MCF7 breast cancer; however, 3 8 8 higher PDLIM2 levels were found in highly invasive triple negative MDA-MB-231, supporting the 3 8 9
connection of PDLIM2 to metastatic potential. Higher levels of PDLIM2 were also found in normal 3 9 0 MCF10A cells (Additional file 11: Figure S11 ), in agreement with its tumor suppressor role in normal 3 9 1 breast cells. This is in principal agreement with our breast cancer tissue data that showed a high 3 9 2 PDLIM2 level in primary tumors forming lymph node metastases, but specifically in small (T1) 3 9 3 luminal A grade 1 tumors (Additional file 13: Table S2 ), which represent the early phase of tumor 3 9 4 development. Conversely, the epithelial marker KRT18 was significantly downregulated in PDLIM2-3 9 5 rich luminal A tumors forming lymph node metastases (Additional file 14: Table S3 ), further 3 9 6
supporting the PDLIM2 connection with mesenchymal phenotype in tissues. Taken together, these 3 9 7
data suggest a connection between PDLIM2 and metastatic phenotype in luminal A tumors and its 3 9 8 distinct roles in different phases of cancer development. Deregulation of PDLIM2 has been associated with oncogenesis, including lymph node metastasis of 4 0 1 breast cancer [5] . The PDLIM2 gene is repressed in different cancers, which implies its tumor 4 0 2 suppressive role. Repression and a tumor suppressive role of PDLIM2 were observed in ATL induced 4 0 3 by HTLV1 virus [26] [27] [28] [29] [34, 35] . In contrast to the above studies, a pro-4 0 5 oncogenic role and enhanced expression of PDLIM2 were observed in castration-resistant prostate 4 0 6 cancer cells [5, 9, 36] , invasive breast cancer cell lines and breast carcinomas [9, 11] . The aim of the 4 0 7 study presented here was to understand the role of PDLIM2 at both the molecular and cellular levels in 4 0 8 the breast cancer context in more detail using in vitro experiments. 4 0 9 PDLIM2 role in MCF7 breast cancer cells 4 1 0
Our data indicate a positive role for PDLIM2 in EMT induction ( Fig. 1A and Additional file 2: Figure  4 1 1 S2), which was previously described in DU145 prostate cancer cells and MDA-MB-231 highly 4 1 2 invasive breast cancer cells [9, 36] . We for the first time report this role in MCF7 cells, a model of 4 1 3 luminal A tumors, confirming the previous data from our clinical set of luminal A breast cancer tissues 4 1 4
[5]. Overexpression of PDLIM2 also denotes disturbance of the β 1-integrin pathway and loss of the 4 1 5 epithelial phenotype via increased levels of FAK, the regulator of the β 1-integrin pathway [10] . Apart 4 1 6 from the above, the stiffness of MCF7 cells was significantly augmented after PDLIM2 4 1 7 overexpression ( Fig. 1B-C) . Increased cell stiffness is typical for cells with a mesenchymal phenotype 4 1 8
[28], which again supports the PDLIM2 role in EMT induction. Moreover, EMT induction by TGFβ1 4 1 9 treatment and/or long-term hypoxia increases PDLIM2 levels ( Fig. 2A , Additional file 4: Figure S4 ). 4 2 0
Our experiments also revealed a reciprocal connection between PDLIM2 and the response to hypoxia 4 2 1 (Fig, 2B, 2C , Additional file 5: Figure S5 and Additional file 6: Figure S6 ), which represents 4 2 2 completely new information that deserves further examination. Furthermore, the observed negative 4 2 3 effects of PDLIM2 on the levels of proteins involved in DNA repair and cell cycle regulation via p53 4 2 4 and especially p-p53 (S20) [39] [40] [41] indicate the relation between PDLIM2 and these processes in 4 2 5 MCF7 cells ( Fig. 2D and Additional file 7: Figure S7 ). All of these results confirm the involvement of 4 2 6 PDLIM2 in the regulation of EMT induction and in the maintenance of the cellular phenotype in 4 2 7 MCF7 cells. Additionally, involvement of PDLIM2 in the response to hypoxia and the effect of 4 2 8 PDLIM2 overexpression on key cancer molecular players suggest a pro-oncogenic role of PDLIM2 in 4 2 9 MCF7 cells, further validating our previous data from clinical tissues [5] . 
